MedPath

Comparison of the effect of cyclosporine and etanercept on Toxic epidermal necrolysis

Phase 2
Conditions
toxic epidermal necrolysis.
Toxic epidermal necrolysis [Lyell]
L51.2
Registration Number
IRCT20191020045169N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

Patients with toxic epidermal necrolysis confirmed by a dermatologist.

Exclusion Criteria

patients with any acquired or congenital immune deficiency.
patients with stage 3 or 4 of heart failure.
patients with uncontrolled hypertension.
patients with renal failure.
patients with known hypersensitivity to these drugs.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eisions re-epithelialization of the toxic epidermal necrolysis. Timepoint: daily, during patients admission. Method of measurement: by dermatologist examination and taking standard pictures from patients lesions.
Secondary Outcome Measures
NameTimeMethod
Mortality rate of the patients. Timepoint: During their admission in the hospital. Method of measurement: SCORTEN index.
© Copyright 2025. All Rights Reserved by MedPath